Rhelion Life Sciences Corp. RHEL
CNSX
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -21.70% | -30.40% | -37.64% | -41.20% | -24.91% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -21.70% | -30.40% | -37.64% | -41.20% | -24.91% |
| Cost of Revenue | -29.16% | -29.07% | -32.26% | -37.19% | -18.50% |
| Gross Profit | -8.74% | -32.48% | -46.03% | -47.09% | -33.93% |
| SG&A Expenses | 5.61% | -6.90% | -22.24% | -29.38% | -29.55% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | 100.00% | 100.00% | -- |
| Total Operating Expenses | -2.03% | -12.62% | -24.30% | -30.86% | -28.07% |
| Operating Income | -17.26% | -8.32% | 9.64% | 19.98% | 30.93% |
| Income Before Tax | -75.69% | -66.36% | 14.74% | 27.02% | 41.13% |
| Income Tax Expenses | -128.44% | -211.84% | -581.77% | -378.46% | -217.88% |
| Earnings from Continuing Operations | -74.01% | -62.81% | 17.09% | 29.08% | 42.62% |
| Earnings from Discontinued Operations | -420.63% | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 197.89% | 184.71% | 102.03% | 156.29% | 117.35% |
| Net Income | -81.25% | -51.96% | 21.20% | 33.58% | 46.85% |
| EBIT | -17.26% | -8.32% | 9.64% | 19.98% | 30.93% |
| EBITDA | -57.21% | -48.34% | -0.97% | 15.56% | 31.52% |
| EPS Basic | -67.16% | -47.22% | 23.01% | 35.00% | 48.46% |
| Normalized Basic EPS | 5.71% | 5.41% | 14.29% | 27.78% | 41.67% |
| EPS Diluted | -186.57% | -158.33% | 23.01% | 35.00% | 48.46% |
| Normalized Diluted EPS | 5.71% | 5.41% | 14.29% | 27.78% | 41.67% |
| Average Basic Shares Outstanding | 11.59% | 3.86% | 3.17% | 2.54% | 2.05% |
| Average Diluted Shares Outstanding | 11.59% | 3.86% | 3.17% | 2.54% | 2.05% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |